

Table S1 Proportion of patients with HER-2 negative breast cancer after PSM who underwent surgery and those who underwent NAT

Variables	Surgery		NAT		P value
	No.	%	No.	%	
Age (years)					0.466
<80	289	66.90	299	69.20	
≥80	143	33.10	133	30.80	
Marital					0.366
Married	159	36.80	175	40.50	
Single	48	11.10	38	8.80	
Divorced	225	52.10	219	50.70	
Race					0.148
White	331	76.60	353	81.70	
Black	63	14.60	53	12.30	
Others	38	8.80	26	6.00	
Grade					0.676
Grade I + II	260	60.20	266	61.60	
Grade III + IV	172	39.80	166	38.40	
Stage					0.866
Stage II	88	20.40	90	20.80	
Stage III	344	79.60	342	79.20	
T stage					0.630
T3	243	56.30	250	57.90	
T4	189	43.80	182	42.10	
N stage					0.679
N0	146	33.80	140	32.40	
N1	167	38.70	161	37.30	
N2	77	17.80	78	18.10	
N3	42	9.70	53	12.30	
ER status					0.284
Negative	70	16.20	82	19.00	
Positive	362	83.80	350	81.00	
PR status					0.395
Negative	149	34.50	161	37.30	
Positive	283	65.50	271	62.70	

ER, estrogen receptor; HER-2, human epidermal growth factor receptor 2; NAT, neoadjuvant therapy; PR, progesterone receptor; PSM, propensity score matching.